| 生物活性 |
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen with oral efficacy and blood-brain barrier permeability, which induces acute leukemia cell death and drives necroptosis (Apoptosis) by activating the RIPK1/RIPK3/MLKL pathway, inhibits breast cancer cell proliferation and induces apoptosis and autophagy (Autophagy) by upregulating the expression of NOXA, PARP, and caspase-3 and activating AMPK, inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway, alleviates mouse liver injury by regulating the Nrf2-STING signaling pathway, alleviates liver injury by regulating anti-inflammatory responses and downregulating 11β-HSD2 expression, induces ferroptosis (Ferroptosis) and overcomes radiotherapy resistance through the PPARγ-ATF3-Gpx4 signaling pathway in non-small cell lung cancer, exhibits inhibitory effects on platelet aggregation, suppresses febrile seizures by inhibiting AMPA receptor activity, and reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling, and can be used for research related to acute leukemia, breast cancer, PM2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, platelet hyperaggregation-related cardiovascular diseases, febrile seizures, and depression-like phenotypes. |
体外研究 (In Vitro) |
Jujuboside B (40-200 μM; 24-72 h) 可呈剂量和时间依赖性降低 U937、HL-60、Jurkat 和 Kasumi-1 急性白血病细胞系的活力,降低原代人急性髓系白血病 (AML) 细胞的存活率。 Jujuboside B (0-120 μM; 2 weeks) 可显著降低 U937 急性白血病细胞的克隆形成能力。 Jujuboside B (40-120 μM; 24 h) 通过 RIPK1/RIPK3/MLKL 通路介导 U937 急性白血病细胞发生坏死性凋亡,上调 U937 急性白血病细胞中 RIPK1、RIPK3 和 MLKL 的总蛋白水平与磷酸化水平。 Jujuboside B (20-100 μM; 72 h) 可强效抑制 MDA-MB-231 (IC50 = 54.38 μM) 和 MCF-7 (IC50 = 74.94 μM) 人乳腺癌细胞的增殖,处理时间为 72 h。 Jujuboside B (25-75 μM; 10-14 days) 可降低 MDA-MB-231 和 MCF-7 人乳腺癌细胞的克隆形成存活率。 Jujuboside B (25-75 μM; 16-48 h) 可呈剂量依赖性地抑制人乳腺癌 MDA-MB-231 细胞的迁移,诱导人乳腺癌细胞 MDA-MB-231 和 MCF-7 发生剂量依赖性凋亡,上调人 MDA-MB-231 细胞和 MCF-7 细胞中凋亡标志物剪切型 PARP 及剪切型 caspase-3 的表达,上调 MDA-MB-231 和 MCF-7 中 NOXA 的表达,激活 AMPK。 Jujuboside B (25-75 μM; 12-48 h) 可在人乳腺癌细胞 MDA-MB-231 和 MCF-7 中诱导呈剂量依赖性和时间依赖性的自噬,增强LC3-I 向 LC3-II 的转化以及降低 p62 表达水平,在人乳腺癌 MCF-7 细胞中呈 AMPK 依赖性诱导自噬。 Jujuboside B (1-100 μM; 8-48 h) 可剂量依赖性地抑制 HUVEC 的细胞活力,抑制 HUVEC 的迁移,抑制 Matrigel 上 HUVEC 的管形成,而对 HCT-15 细胞活力的影响极小。 Jujuboside B (1-100 μM; 24 h) 可呈剂量依赖性地将 HUVECs 阻滞于细胞周期的 G0/G1 期。 Jujuboside B (1-100 μM; 30 min pre-incubation) 可呈剂量依赖性地阻断 VEGF165 诱导的 HUVEC 中 VEGFR2 及其下游介导因子 (Akt、FAK、Src、PLCγ1) 的磷酸化。 Jujuboside B (100 μM; 24 h) 在 A549 和 H460 细胞中对 100 ng/mL DR4 和 DR5 蛋白水平的调控效果优于单独处理。 Jujuboside B (30-300 μM; 5 min) 可剂量依赖性地抑制胶原、凝血酶、Arachidonic acid (AA) (MS-A69140) 和二磷酸腺苷 (ADP) 诱导的大鼠富血小板血浆聚集,其中对胶原、凝血酶和 AA 诱导的聚集的 IC50 值分别为 92.1 μM、201.5 μM 和 95.2 μM,且在 300 μM 浓度下不会产生血小板细胞毒性。 Jujuboside B (30-300 μM; 预处理 5 分钟,胶原孵育 6 分钟) 抑制胶原诱导的大鼠富血小板血浆中 TXA2 的生成。 Jujuboside B (30-100 μM) 可在体外以剂量依赖的方式抑制 HEK293 细胞中重组 GluA1/GluA2 AMPA 受体的电流。 Jujuboside B (AMPA 刺激前预孵育 1 min,浓度 10 μM) 可显著抑制原代培养大鼠皮质神经元中 AMPA 诱导的细胞内钙升高,降低钙反应的峰值和累积值。 Jujuboside B (20-100 μM; 60 μM for viability, colony formation, pathway analysis) 可抑制 A549 细胞的活力与集落形成,并通过降低关键通路组分的磷酸化水平阻断 PI3K/Akt 和 MAPK/ERK 信号通路,其 IC50 为 60 μM。
Cell Viability Assay
| Cell Line: |
U937, HL-60, Jurkat, Kasumi-1 acute leukemia cell lines |
| Concentration: |
40, 80, 100, 120, 160, 200 μM |
| Incubation Time: |
24 h; 48 h; 72 h |
| Result: |
Inhibited the growth of all four leukemia cell lines in a dose- and time-dependent manner. Showed significant inhibitory effects after 24-h treatment, with potency increasing at longer incubation times. |
Cell Proliferation Assay
| Cell Line: |
U937 acute leukemia cells |
| Concentration: |
40, 80, 120 μM |
| Incubation Time: |
2 weeks |
| Result: |
Significantly inhibited colony formation of U937 cells at 80 μM and 120 μM, reflected by decreased colony number and size. Did not significantly affect colony counts at 40 μM. |
Western Blot Analysis
| Cell Line: |
U937 acute leukemia cells |
| Concentration: |
40, 80, 120 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly increased protein levels of RIPK1, p-RIPK1, RIPK3, p-RIPK3, MLKL, and p-MLKL in U937 cells in a dose-dependent manner. Induced statistically significant upregulation of all target proteins and their phosphorylated forms at 80 μM and 120 μM. |
Cell Viability Assay
| Cell Line: |
MDA-MB-231, MCF-7 human breast cancer cell lines |
| Concentration: |
0, 40, 60, 80, and 100 μM |
| Incubation Time: |
72 h |
| Result: |
Significantly inhibited the proliferation of MDA-MB-231 and MCF-7 in a dose-dependent manner. Achieved an IC50 of 54.38 μM for MDA-MB-231 and 74.94 μM for MCF-7. |
Cell Migration Assay
| Cell Line: |
MDA-MB-231 human breast cancer cell line |
| Concentration: |
25, 50, 75 μM |
| Incubation Time: |
16 h |
| Result: |
Inhibited the migration of MDA-MB-231 cells in a dose-dependent manner, with significant reductions in migrated cell numbers at all tested concentrations. |
Apoptosis Analysis
| Cell Line: |
MDA-MB-231, MCF-7 human breast cancer cell lines |
| Concentration: |
25, 50, 75 μM |
| Incubation Time: |
48 h |
| Result: |
Resulted in a remarkable dose-dependent increase in the apoptotic cell population (early apoptotic Annexin V(+)/PI(−) and late apoptotic Annexin V(+)/PI(+) cells) in both cell lines. |
Western Blot Analysis
| Cell Line: |
MDA-MB-231, MCF-7 human breast cancer cell lines |
| Concentration: |
25, 50, 75 μM |
| Incubation Time: |
48 h |
| Result: |
Significantly increased the expression of cleaved PARP and cleaved caspase-3 in a dose-dependent manner in both cell lines.\nRemarkably elevated NOXA expression in a dose-dependent pattern in both cell lines.\nIncreased phosphorylated AMPK levels in a dose-dependent manner in both cell lines. |
Western Blot Analysis
| Cell Line: |
MDA-MB-231, MCF-7 human breast cancer cell lines |
| Concentration: |
25-75 μM (48 h treatment); 50 μM (12-48 h treatment) |
| Incubation Time: |
48 h (dose-dependent autophagy); 12-48 h (time-dependent autophagy) |
| Result: |
Increased the conversion of LC3-I to LC3-II in a dose-dependent manner after 48 h of treatment. Accumulated LC3-II in a time-dependent manner from 12 to 48 h of treatment at 50 μM. Decreased p62 expression in a dose-dependent manner after 48 h of treatment in both cell lines. |
Cell Viability Assay
| Cell Line: |
human umbilical vein endothelial cells (HUVECs), HCT-15 human colorectal adenocarcinoma cells |
| Concentration: |
1, 3, 10, 30, and 100 μM |
| Incubation Time: |
48 h |
| Result: |
Significantly suppressed HUVEC viability in a dose-dependent manner, with minimal effect at 1-10 μM and strong suppression at ≥30 μM. Maintained over 65% of HCT-15 cell viability across all tested concentrations. |
Cell Cycle Analysis
| Cell Line: |
HUVECs |
| Concentration: |
1, 3, 10, 30, and 100 μM |
| Incubation Time: |
24 h |
| Result: |
Caused dose-dependent changes in the percentage of cells in G0/G1 and S phases, indicating G0/G1 phase arrest. |
Cell Migration Assay
| Cell Line: |
HUVECs |
| Concentration: |
1, 3, 10, 30, and 100 μM |
| Incubation Time: |
10 h |
| Result: |
Inhibited HUVEC migration in a dose-dependent manner, with ~20% inhibition at 3 μM and ~90% inhibition at 100 μM. |
Western Blot Analysis
| Cell Line: |
HUVECs |
| Concentration: |
1, 3, 10, 30, and 100 μM |
| Incubation Time: |
30 min (pre-incubation prior to VEGF165 stimulation) |
| Result: |
Inhibited phosphorylation of VEGFR2 in a dose-dependent manner. Inhibited phosphorylation of downstream signaling proteins (Akt, FAK, Src, PLCγ1) in a dose-dependent manner. |
Western Blot Analysis
| Cell Line: |
A549, H460 |
| Concentration: |
100 μM (combined with 100 ng/mL TRAIL) |
| Incubation Time: |
24 h |
| Result: |
Upregulated DR4 and DR5 protein levels more significantly than jujuboside B or TRAIL alone in A549 and H460 cells. |
|
体内研究 (In Vivo) |
Jujuboside B (i.p.;每日 1 次;连续 17 天;20 mg/kg) 可显著抑制裸鼠体内 MCF-7、MDA-MB-231 乳腺癌异种移植物的生长,同时会诱导肿瘤细胞凋亡和自噬,且未观察到对动物体重产生影响。 Jujuboside B (0.1-0.8 mg/kg;i.v.;2 天内 3 次) 可通过调控 TLR2/4-MyD88 及 mTOR-自噬通路,减轻炎症、细胞凋亡与自噬功能障碍,从而显著缓解 BALB/c 小鼠中 PM2.5 诱导的肺损伤。 Jujuboside B (i.p./i.v.;每日 1 次;连续 7 天/单次给药,20-40 mg/kg/0.4-1.5 mg/kg) 可剂量依赖性地改善 Acetaminophen (MS-H20928 ) 诱导的雄性 C57BL/6 J 小鼠急性肝损伤,同时抑制氧化应激、炎症反应、细胞凋亡及 STING 通路激活,并激活 Nrf2 通路;可通过减轻炎症、增强抗氧化能力、上调 GR 表达以及下调 11β-HSD2 表达,呈剂量依赖性地保护雄性 C57BL/6 小鼠免受盲肠结扎穿孔术 (CLP) 诱导的肝损伤。 Jujuboside B (i.p.,每 2 天 1 次,7 次,剂量为 20 mg/kg) 可通过抗血管生成和抗增殖机制使雌性 BALB/c 裸鼠的皮下 HCT-15 结直肠癌肿瘤体积减少 55.5%、肿瘤重量降低 56.3%,且未观察到与治疗相关的体重减轻。 Jujuboside B (1–100 μM) 局部作用于鸡胚尿囊膜时,可呈剂量依赖性抑制新生血管生成,100 μM 浓度下抑制率可达 80%。 Jujuboside B (10-100 μM; 掺入皮下 Matrigel 栓) 被掺入皮下 Matrigel 栓后,可呈剂量依赖性抑制雌性 BALB/c 小鼠体内 VEGF 诱导的血管生成。 Jujuboside B (i.p.,每隔 1 天 1 次,20-40 mg/kg) 可呈剂量依赖性地减小裸鼠体内 A549 非小细胞肺癌的肿瘤体积,且不会引发明显的肝毒性或肾毒性。 Jujuboside B (10-100 mg/kg;p.o.;单次给药) 可对雄性 ICR 小鼠中由胶原蛋白和肾上腺素诱导的急性肺血栓栓塞提供具有统计学显著性的 63%保护作用。 Jujuboside B (10-50 mg/kg;i.p.;高热诱导前 1 小时单次给药) 可剂量依赖性地抑制 P14 雄性 C57BL/6 小鼠的热性惊厥严重程度。 Jujuboside B (40 mg/kg/天;i.p.;每日;持续 2 周) 可通过调控凋亡相关蛋白、阻断 PI3K/Akt 及 MAPK/ERK 信号通路、降低炎性细胞因子水平,在非应激和 CUMS 应激荷瘤雌性 C57BL/6 小鼠中显著抑制肺癌进展。 Jujuboside B (40 mg/kg;i.p.;每日;持续 2 周) 可通过提升血清 5-HT 与色氨酸水平、改善行为学评分及降低炎症细胞因子水平,显著改善经 CUMS 造模的雌性 C57BL/6 小鼠的抑郁样行为。
| Animal Model: |
athymic BALB/c nude (female, 5-6-week-old) |
| Dosage: |
20 mg/kg |
| Administration: |
i.p.; daily; 17,28 days |
| Result: |
Significantly inhibited MCF-7 tumor growth, with tumor volumes and final tumor weights markedly lower than the control group. Showed no significant difference in animal body weight compared with the control group. Elevated expression of cleaved PARP, cleaved caspase-3, and LC3-II in tumor tissue, indicating induction of apoptosis and autophagy. Significantly inhibited MDA-MB-231 tumor growth, with tumor volumes and final tumor weights markedly lower than the control group. Showed no significant difference in animal body weight compared with the control group. Elevated expression of cleaved PARP, cleaved caspase-3, and LC3-II in tumor tissue, indicating induction of apoptosis and autophagy.
|
| Animal Model: |
BALB/c (7-week-old; acclimated for 12 days; PM2.5-induced lung injury model) |
| Dosage: |
0.1 mg/kg; 0.4 mg/kg; 0.8 mg/kg |
| Administration: |
i.v.; three times over 2 days |
| Result: |
Significantly reduced the PM2.5-induced increase in lung wet/dry weight ratio, total cell count in BALF, total neutrophil count in BALF, and lung injury score. Significantly reversed PM2.5-induced changes in apoptotic protein levels: restored anti-apoptotic Bcl-2 levels, reduced pro-apoptotic Bax, cleaved caspase-3, and cleaved PARP levels, and decreased the TUNEL-positive apoptotic cell percentage. Significantly reduced PM2.5-induced increases in pro-inflammatory cytokines IFN-γ, IL-1β, IL-6, IL-18, and TNF-α, and restored PM2.5-induced decreases in anti-inflammatory cytokines IL-2, IL-4, and IL-10. Significantly inhibited PM2.5-induced upregulation of autophagy-related proteins LC3 II and Beclin 1, reversed PM2.5-induced increases in TLR2, TLR4, and MyD88 levels, and restored PM2.5-induced reductions in phosphorylated mTOR, Akt, and PI3K levels. |
| Animal Model: |
C57BL/6 J (male, 8 weeks old, Acetaminophen-induced acute hepatotoxicity) |
| Dosage: |
20 mg/kg; 40 mg/kg |
| Administration: |
i.p.; daily; 7 days |
| Result: |
Reversed acetaminophen-induced CYP2E1 upregulation in liver tissue in a dose-dependent manner. Reduced acetaminophen-induced mortality from 80% to 30% over 48 hours (40 mg/kg dose). Dose-dependently reduced serum ALT, AST, and LDH levels, improved liver histopathological scores, and attenuated liver tissue necrosis compared to acetaminophen-only controls. Dose-dependently suppressed acetaminophen-induced increases in serum and liver TNF-α, IL-6, and IFN-β levels, reduced liver macrophage infiltration (F4/80-positive cells), and lowered liver TNF-α and IL-6 protein expression. Dose-dependently reversed acetaminophen-induced increases in liver 4-HNE and MDA levels, restored liver GSH, SOD, and CAT activities, upregulated liver SOD1 and SOD2 mRNA levels, downregulated liver NOX2 and COX2 mRNA levels, reduced hepatocyte apoptosis (increased Bcl-2/Bax ratio, decreased cleaved caspase-3), inhibited acetaminophen-induced STING pathway activation (reduced STING, p-IRF3, and p-p65 protein levels in liver tissue), and activated the Nrf2 pathway (increased total, nuclear, and cytosolic Nrf2 protein levels, upregulated liver HO-1 and NQO-1 protein and mRNA levels). |
| Animal Model: |
C57BL/6 (male, 8-10 weeks old, average weight 27 g, CLP-induced sepsis) |
| Dosage: |
0.4 mg/kg; 0.75 mg/kg; 1.5 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Significantly reduced CLP-induced hepatic histopathological damage, including hemorrhagic necrosis, portal inflammation, parenchymal necrosis, and inflammatory cell infiltration at 0.75 mg/kg and 1.5 mg/kg. Significantly reduced elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels at 0.75 mg/kg and 1.5 mg/kg. Significantly reduced elevated liver tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and nitric oxide (NO) levels at 0.75 mg/kg and 1.5 mg/kg; significantly reduced elevated liver TNF-α and NO levels at 0.4 mg/kg. Reduced elevated liver malondialdehyde (MDA) levels at 0.75 mg/kg and 1.5 mg/kg. Restored reduced liver glutathione (GSH), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) activity at 0.75 mg/kg and 1.5 mg/kg. Increased reduced liver glucocorticoid receptor (GR) protein expression at 0.4 mg/kg, 0.75 mg/kg, and 1.5 mg/kg. Reduced elevated liver 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) protein expression, with no effect on 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) expression at 0.75 mg/kg and 1.5 mg/kg. Did not significantly reduce serum ALT/AST levels or liver IL-1β levels at 0.4 mg/kg. |
| Animal Model: |
BALB/c nude (female) |
| Dosage: |
20 mg/kg |
| Administration: |
i.p.; once every two days; 7 total doses |
| Result: |
Reduced mean tumor volume by 55.5% compared to control group. Reduced mean tumor weight by 56.3% compared to control group. Significantly reduced tumor microvessel density. Significantly decreased Ki67-positive proliferative tumor cells. Significantly increased tumor necrosis area relative to controls. Caused no significant mouse body weight loss during treatment. |
| Animal Model: |
BALB/c nude (female, 6 weeks old) |
| Dosage: |
20 mg/kg; 40 mg/kg |
| Administration: |
i.p.; every other day |
| Result: |
Reduced tumor volumes in a dose-dependent manner relative to controls, with statistically significant reductions observed over the study period. Showed no significant difference in body weights between treated and control groups. Exhibited no significant difference in serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (CRE) from controls. |
| Animal Model: |
ICR mice (male, 35-40 g) |
| Dosage: |
10 mg/kg; 30 mg/kg; 100 mg/kg |
| Administration: |
p.o.; single dose |
| Result: |
Provided 17% protection against thromboembolism. Provided 43% protection against thromboembolism. Provided 63% protection against thromboembolism, which was statistically significant compared to vehicle. |
| Animal Model: |
C57BL/6 (male, postnatal day 14, 6-7 g, LPS-primed hyperthermic induction) |
| Dosage: |
10 mg/kg; 30 mg/kg; 50 mg/kg |
| Administration: |
i.p.; single dose 1 hour before hyperthermic induction |
| Result: |
Increased seizure latency to 228.7, reduced the percentage of grade 5 seizures to 50%, and decreased seizure severity (Racine score) to 4.5. Significantly prolonged seizure latency to 563.3s, eliminated grade 5 seizures (90% of mice exhibited maximum grade 3 seizures), decreased seizure severity (Racine score) to 2.9, prolonged latency to EEG seizure onset to 680.0s, shortened total seizure duration to 551.9s, decreased seizure spike number to 39.88, and reduced hippocampal c-Fos-positive cells to 15.50 cells/mm2. Significantly prolonged seizure latency to 737.2 s, eliminated grade 5 seizures (80% of mice exhibited maximum grade 3 seizures), and decreased seizure severity (Racine score) to 2.8. |
| Animal Model: |
C57BL/6 (female, 8 weeks old, subcutaneous inoculation of LLC lung cancer cells; chronic unpredictable mild stress exposure) |
| Dosage: |
40 mg/kg/day |
| Administration: |
i.p.; daily; 2 weeks |
| Result: |
Significantly reduced tumor volume and weight compared to vehicle controls in non-CUMS tumor-bearing mice. Significantly reduced tumor volume and weight compared to vehicle-treated CUMS-exposed tumor-bearing mice, reversing CUMS-promoted tumor progression. Significantly increased proapoptotic Bax protein and mRNA expression, and decreased antiapoptotic Bcl-2 protein and mRNA expression in tumor tissues compared to corresponding vehicle controls. Significantly reduced phosphorylation levels of PI3K, Akt, MAPK, ERK, and CREB in tumor tissues compared to corresponding vehicle controls. Significantly decreased serum levels of inflammatory cytokines TNF-α, IL-4, IL-6, and IL-10 compared to vehicle controls. |
| Animal Model: |
C57BL/6 (female, 8 weeks old, chronic unpredictable mild stress exposure) |
| Dosage: |
40 mg/kg/day |
| Administration: |
i.p.; daily; 2 weeks |
| Result: |
Significantly increased serum 5-HT and tryptophan levels compared to vehicle-treated CUMS-exposed mice. Significantly increased sucrose preference, locomotion scores, and exploratory scores compared to vehicle-treated CUMS-exposed mice, ameliorating depression-like phenotypes. Significantly decreased serum levels of inflammatory cytokines TNF-α, IL-4, IL-6, and IL-10 compared to vehicle controls. |
|